Abilene and Austin, TX -- March 10, 2010 -- Receptor Logic, Inc. announced today that Chief Scientist Jon Weidanz, Ph.D., will be a presenter at the Gordon Research Conference on Antibody Biology and Engineering, Thursday, March 11, 2010, in Ventura, California. Dr. Weidanz will be speaking on the “Therapeutic potential of T-cell receptor mimic monoclonal antibodies.” His presentation will focus on Receptor Logic’s development of TCRm monoclonal antibodies (mAbs) that promise access to new patient populations in both oncology and infectious disease indications. The company’s technology also provides a disruptive and expansive effect in the therapeutic mAb marketplace through new biomarkers that can be targeted for the elimination of diseased tissues.
Dr. Jon Weidanz is founder and Chief Scientist of Receptor Logic. He also is the founding active Director for the Center for Immunotherapeutic Research, Abilene, Texas, and is a tenured associate professor at Texas Tech University Health Science Center. In addition to advancing the science of immunotherapy, Dr. Weidanz is a popular speaker, instructor and author in the fields of immunology and immunodiagnostics. He has 13 pending or issued patents and has received $19M in awards for a variety of research pursuits including the NIH and NIST.
The Gordon Research Conference attracts top scientists from around the world. The Antibody Biology and Engineering conference includes speakers from MIT, Harvard Medical School, Scripps Research Institute, Pfizer, Yale, the University of Tokyo, and the National Institute of Immunology, New Delhi.
About Receptor Logic, Inc.
Receptor Logic, Inc. is a biopharmaceutical company specializing in high-quality antibodies that mimic the specificity of T-Cell Receptors in the immune system. T-Cell Receptor mimics (TCRm) offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines. Receptor Logic is funded and managed by Emergent Technologies, Inc, (ETI), a unique life sciences investment and management company pioneering a novel business approach to early stage funding and development of scientific discoveries originating at universities and research institutions. For more information, please visit the company website www.receptorlogic.com.
